Interactive Features

Quiz

Quiz: Treatment-Related Adverse Events in Patients with NSCLC Treated With Tiragolumab Plus Atezolizumab

09/08/2022

What did the phase 2 CITYSCAPE trial find to be the most common treatment-related adverse event in patients with non-small cell lung cancer treated with a combination of tiragolumab and atezolizumab?

What did the phase 2 CITYSCAPE...

09/08/2022

Oncology

Quiz

Quiz: Agradasib-Related Adverse Events in Patients With KRAS-Mutated NSCLC

09/08/2022

According a phase 2 study, what percentage of patients with KRASG12C-mutated NSCLC experienced treatment-related adverse events when treated with adagrasib?

According a phase 2 study, what...

09/08/2022

Oncology

Quiz

Novel MS-VMAT Technique for Whole Lung Irradiation

03/15/2022

At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.

At the 2022 ACRO Annual Meeting,...

03/15/2022

Oncology

Test Your Knowledge

Quiz: Is Lurbinectedin Beneficial for Patients with Pretreated SCLC and Mesothelioma?

12/09/2021

True or false: According to real-world data, lurbinectedin did not demonstrate clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma.

True or false: According to...

12/09/2021

Oncology

Quiz

Quiz: Dose Escalation in Esophageal Cancer

08/15/2021

True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.

True or false: According to...

08/15/2021

Oncology

Test Your Knowledge

Quiz: Pembrolizumab Plus CRT for Locally Advanced NSCLC

08/09/2021

True or false: Pembrolizumab in combination with concurrent chemoradiation therapy offered promising clinical activity in patients with locally advanced non-small cell lung cancer.

True or false: Pembrolizumab in...

08/09/2021

Oncology

Test Your Knowledge

Quiz: Is Pralsetinib Beneficial for RET+ NSCLC?

08/06/2021

True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.

True or false: Oral pralsetinib...

08/06/2021

Oncology

Test Your Knowledge

Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?

08/03/2021

The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.

The combination of...

08/03/2021

Oncology

Test Your Knowledge

Quiz: Which treatment benefits patients with KRAS p.G12C-mutated non-small cell lung cancer?

07/06/2021

Which treatment showed efficacy and manageable safety in patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer?

Which treatment showed efficacy...

07/06/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Received FDA Approval for ALK+ NSCLC?

03/23/2021

Which of the following treatments recently received FDA approval for ALK+ Non-Small Cell Lung Cancer?

Which of the following...

03/23/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology